Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

Por Follows, Richard MA, Snowise, Neil G, Ho, Shu-Yen, Ambery, Claire L, Smart, Kevin, McQuade, Barbara A
Publicado em 2013

Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist

Por Holland, Carlijn, Drunen, Cornelis Van, Denyer, Jane, Smart, Kevin, Segboer, Christine, Terreehorst, Ingrid, Newlands, Amy, Beerahee, Misba, Fokkens, Wytske, Tsitoura, Daphne C
Publicado em 2014

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

Por Miller, Bruce E., Mistry, Sunil, Smart, Kevin, Connolly, Paul, Carpenter, Donald C., Cooray, Hiran, Bloomer, Jackie C., Tal-Singer, Ruth, Lazaar, Aili L.
Publicado no BMC Pharmacol Toxicol (2015)

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

Por Miller, Bruce E., Smart, Kevin, Mistry, Sunil, Ambery, Claire L., Bloomer, Jackie C., Connolly, Paul, Sanderson, Dominic, Shreeves, Trevor, Smith, Rachel, Lazaar, Aili L.
Publicado em 2014